Cancer Letters,
Journal Year:
2024,
Volume and Issue:
600, P. 217185 - 217185
Published: Aug. 12, 2024
Glioblastoma,
a
highly
malignant
intracranial
tumor,
has
acquired
slow
progress
in
treatment.
Previous
clinical
trials
involving
targeted
therapy
and
immune
checkpoint
inhibitors
have
shown
no
significant
benefits
treating
glioblastoma.
This
ineffectiveness
is
largely
due
to
the
complex
immunosuppressive
environment
of
Glioblastoma
cells
exhibit
low
immunogenicity
strong
heterogeneity
microenvironment
replete
with
inhibitory
cytokines,
numerous
cells,
insufficient
effective
T
cells.
Fortunately,
recent
Phase
I
CART
for
glioblastoma
confirmed
its
safety,
small
subset
patients
achieving
survival
benefits.
However,
continues
face
challenges,
including
blood-brain
barrier
obstruction,
antigen
loss,
an
tumor
(TME).
article
provides
detailed
examination
glioblastoma's
microenvironment,
both
from
intrinsic
extrinsic
cell
factors,
reviews
current
basic
research
on
multi-targets
treatment,
concludes
by
outlining
key
challenges
using
therapy.
Frontiers in Oncology,
Journal Year:
2023,
Volume and Issue:
13
Published: Sept. 13, 2023
Angiogenic
growth
factors
(AGFs)
are
a
class
of
secreted
cytokines
related
to
angiogenesis
that
mainly
include
vascular
endothelial
(VEGFs),
stromal-derived
factor-1
(SDF-1),
platelet-derived
(PDGFs),
fibroblast
(FGFs),
transforming
factor-beta
(TGF-β)
and
angiopoietins
(ANGs).
Accumulating
evidence
indicates
the
role
AGFs
is
not
only
limited
tumor
but
also
participating
in
progression
by
other
mechanisms
go
beyond
their
angiogenic
role.
were
shown
be
upregulated
glioma
microenvironment
characterized
extensive
high
immunosuppression.
produced
stromal
cells
can
exert
an
immunomodulatory
interacting
with
immune
cells.
This
review
aims
sum
up
interactions
among
AGFs,
cancer
particular
emphasis
on
tries
provide
new
perspectives
for
understanding
in-depth
explorations
anti-glioma
therapy.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: March 1, 2024
Introduction
Exercise
is
recommended
as
an
adjunct
therapy
in
cancer,
but
its
effectiveness
varies.
Our
hypothesis
that
the
benefit
depends
on
exercise
intensity.
Methods
We
subjected
mice
to
low
intensity
(Li),
moderate
(Mi)
or
high
(Hi)
exercise,
untrained
control
(Co)
groups
based
their
individual
maximal
running
capacity.
Results
found
played
a
critical
role
tumor
control.
Only
Mi
delayed
growth
and
reduced
burden,
whereas
Li
Hi
failed
exert
similar
antitumor
effects.
While
both
normalized
vasculature,
only
increased
infiltrated
CD8+
T
cells,
also
displayed
enhanced
effector
function
(higher
proliferation
expression
of
CD69,
INFγ,
GzmB).
Moreover,
induced
intensity-dependent
mobilization
cells
into
bloodstream.
Conclusion
These
findings
shed
light
intricate
relationship
between
with
implications
for
personalized
optimal
prescriptions
The Journal of Steroid Biochemistry and Molecular Biology,
Journal Year:
2024,
Volume and Issue:
243, P. 106571 - 106571
Published: June 22, 2024
Prostate
cancer
is
primarily
hormone-dependent,
and
medical
treatments
have
focused
on
inhibiting
androgen
biosynthesis
or
signaling
through
various
approaches.
Despite
significant
advances
with
the
introduction
of
receptor
signalling
inhibitors
(ARSIs),
patients
continue
to
progress
castration-resistant
prostate
(CRPC),
highlighting
need
for
targeted
therapies
that
extend
beyond
hormonal
blockade.
Chimeric
Antigen
Receptor
(CAR)
T
cells
other
engineered
immune
represent
a
new
generation
adoptive
cellular
therapies.
While
these
significantly
enhanced
outcomes
hematological
malignancies,
ongoing
research
exploring
broader
use
CAR
therapy
in
solid
tumors,
including
advanced
cancer.
In
general,
cell
are
less
effective
against
cancers
immunosuppressive
tumor
microenvironment
hindering
infiltration,
activation
cytotoxicity
following
antigen
recognition.
addition,
inherent
heterogeneity
exists
may
prevent
durable
therapeutic
responses
using
single-target
agents.
These
barriers
must
be
overcome
inform
clinical
trial
design
improve
treatment
efficacy.
this
review,
we
discuss
innovative
rationally
designed
strategies
under
investigation
translation
immunotherapy
maximise
patients.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics,
Journal Year:
2024,
Volume and Issue:
32(8), P. 1239 - 1256
Published: Jan. 1, 2024
Glioblastoma
multiforme
(GBM)
is
an
aggressive
primary
brain
tumor
characterized
by
extensive
heterogeneity
and
vascular
proliferation.
Hypoxic
conditions
in
the
tissue
microenvironment
are
considered
a
pivotal
player
leading
progression.
Specifically,
hypoxia
known
to
activate
inducible
factors,
such
as
hypoxia-inducible
factor
1alpha
(HIF-1α),
which
turn
can
stimulate
neo-angiogenesis
through
activation
of
various
downward
mediators,
endothelial
growth
(VEGF).
Here,
we
aimed
explore
role
HIF-1α/VEGF
immunophenotypes
alone
combination
with
other
prognostic
markers
or
clinical
image
analysis
data,
potential
biomarkers
GBM
prognosis
treatment
efficacy.
We
performed
systematic
review
(Medline/Embase,
Pubmed
database
search
was
completed
16th
April
2024
two
independent
teams;
PRISMA
2020).
evaluated
methods
immunoassays,
cell
viability,
animal
patient
survival
retrieved
studies
assess
unbiased
data.
used
inclusion
criteria,
evaluation
based
on
expression,
imaging
manifestations
related
application
immunoassays
for
protein
effectiveness
therapeutic
strategies
expression.
exclusion
data
not
reporting
both
HIF-1α
VEGF
prognosis.
included
50
investigating
total
1319
human
specimens,
18
different
lines
GBM-derived
stem
cells,
6
models,
identify
association
immunophenotypes,
macroscopic
approaches.
found
that
increased
expression
correlates
oncogenic
miR-210-3p,
Oct4,
AKT,
COX-2,
PDGF-C,
PLDO3,
M2
polarization,
ALK,
unfavorable
survival.
Reduced
FIH-1,
ADNP,
STAT1
upregulation,
well
manifestations,
like
epileptogenicity,
favorable
GBM.
Based
our
may
be
useful
tool
clarify
MRI-PET
distinguishing
between
progression
pseudoprogression.
Finally,
reflect
efficacy,
including
combined
first-line
histone
deacetylase
inhibitors,
thimerosal,
active
metabolite
irinotecan,
STAT3
inhibitors
alone,
resulting
These
were
supported
variable
evaluate
immunophenotypes.
Data
limitations
include
use
less
sensitive
detection
some
cases.
Overall,
support
HIF-1α/VEGF's
Cancer Letters,
Journal Year:
2024,
Volume and Issue:
600, P. 217185 - 217185
Published: Aug. 12, 2024
Glioblastoma,
a
highly
malignant
intracranial
tumor,
has
acquired
slow
progress
in
treatment.
Previous
clinical
trials
involving
targeted
therapy
and
immune
checkpoint
inhibitors
have
shown
no
significant
benefits
treating
glioblastoma.
This
ineffectiveness
is
largely
due
to
the
complex
immunosuppressive
environment
of
Glioblastoma
cells
exhibit
low
immunogenicity
strong
heterogeneity
microenvironment
replete
with
inhibitory
cytokines,
numerous
cells,
insufficient
effective
T
cells.
Fortunately,
recent
Phase
I
CART
for
glioblastoma
confirmed
its
safety,
small
subset
patients
achieving
survival
benefits.
However,
continues
face
challenges,
including
blood-brain
barrier
obstruction,
antigen
loss,
an
tumor
(TME).
article
provides
detailed
examination
glioblastoma's
microenvironment,
both
from
intrinsic
extrinsic
cell
factors,
reviews
current
basic
research
on
multi-targets
treatment,
concludes
by
outlining
key
challenges
using
therapy.
